Radiotherapy plus concomitant and adjuvant temozolomide for versus radiotherapy alone for newly diagnosed glioblastoma

Two-year survival rate was 26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapy only group


Addition of bevacizumab to radiotherapy and temozolomide for newly diagnosed glioblastoma

Longer progression-free survival (10.6 months vs. 6.2 months) with the addition of bevacizumab


Bevacizumab and lomustine for treating first recurrences

Progression-free survival was 4.17 months with combination treatment vs. 1.54 months of those receiving only lomustine


Cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma

Cediranib produced a modest decreased time to deterioration in neurologic status, corticosteroid-sparing effects